For instance, activin receptor ligand traps displayed preclinical promising efficacy in other diseases, such as Diamond–Blackfan anemia and other types of anemia [13], and Luspatercept could also be assessed in combination with other approved agents for anemia (e.g., ESAs) or with other agents targeting the TGF-β pathway (e.g., Galunisertib) to benefit from potentially synergistic or additive mechanisms of action [63,64]. Here, TGFB1 is linked to anemia.